Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

吉非替尼 医学 危险系数 内科学 置信区间 表皮生长因子受体 无症状的 肿瘤科 随机对照试验 胃肠病学 癌症
作者
Yuankai Shi,Gongyan Chen,Xiang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:17 (11): 1297-1305 被引量:79
标识
DOI:10.1016/j.jtho.2022.07.1143
摘要

Abstract

Introduction

Furmonertinib (AST2818) is a pan-EGFR tyrosine kinase inhibitor with central nervous system (CNS) antitumor activity. We report the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.

Methods

FURLONG was a randomized, double-blind, phase 3 study conducted in 55 hospitals in the People's Republic of China. Patients 1:1 randomly received furmonertinib 80 mg once daily or gefitinib 250 mg once daily treatment. At screening, all the patients underwent brain imaging examination. Patients with asymptomatic steady CNS metastases at baseline constituted this preplanned CNS subgroup analysis.

Results

A total of 358 patients were enrolled in the FURLONG study. In the 133 (37%) patients who had measurable or nonmeasurable CNS lesions, CNS progression-free survival was 20.8 months (95% confidence interval [CI]: 15.2–25.3) in the furmonertinib group and 9.8 months (95% CI: 7.2–18.0) in the gefitinib group (hazard ratio = 0.40 [95% CI: 0.23–0.71], p = 0.0011). In the 60 patients (17%) who had measurable CNS lesions, CNS objective response rate was 91% (95% CI: 72–99) with furmonertinib and 65% (95% CI: 48–80) with gefitinib (OR = 6.82 [95% CI: 1.23–37.67], p = 0.0277). The least-square mean of CNS depth of response was 62% (95% CI: 51–72) in the furmonertinib group and 39% (95% CI: 30–47) in the gefitinib group, the mean difference was 23% (95% CI: 10–37, p = 0.0011).

Conclusions

Furmonertinib first-line treatment was found to have superior efficacy in CNS progression-free survival, CNS objective response rate, and CNS depth of response compared with gefitinib in patients with EGFR-mutated NSCLC with CNS metastases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
h11的应助被Df采纳,获得10
刚刚
manman11完成签到,获得积分10
刚刚
Moony完成签到,获得积分10
刚刚
1秒前
1秒前
sunnymoon发布了新的文献求助10
2秒前
2秒前
zhuzihao发布了新的文献求助10
3秒前
小蘑菇的应助被白嫖论文采纳,获得10
3秒前
4秒前
小白的应助被manman11采纳,获得80
4秒前
隐形曼青的应助被1412采纳,获得10
4秒前
4秒前
5秒前
做科研的小丸子完成签到,获得积分10
5秒前
keyanrubbish完成签到,获得积分10
5秒前
6秒前
栾花花发布了新的文献求助10
6秒前
纯真的翠彤的应助被dilys采纳,获得10
6秒前
华西招生版完成签到,获得积分10
6秒前
ZQP完成签到,获得积分10
7秒前
冬吃萝卜夏吃姜完成签到,获得积分10
7秒前
7秒前
无情的聪健的应助被Foremelon采纳,获得20
7秒前
科研小民工完成签到,获得积分10
7秒前
8秒前
wanci的应助被诚心的弼采纳,获得10
8秒前
zhuzihao完成签到,获得积分10
9秒前
9秒前
10秒前
sunnymoon发布了新的文献求助10
10秒前
小马甲的应助被科研通管家采纳,获得10
10秒前
10秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
10秒前
传奇3的应助被科研通管家采纳,获得10
10秒前
冷艳蝴蝶发布了新的文献求助10
10秒前
慕青的应助被科研通管家采纳,获得10
11秒前
null的应助被科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161211
求助须知:如何正确求助?哪些是违规求助? 9555956
关于积分的说明 21731400
捐赠科研通 7751154
什么是DOI,文献DOI怎么找? 3427515
关于科研通互助平台的介绍 2552568
邀请新用户注册赠送积分活动 2471950